FDA grants priority review status to Lilly, Daiichi's prasugrel

02/21/2008 | Bloomberg11

Eli Lilly and Co. and Daiichi Sankyo Co. on Thursday announced that the FDA has granted priority review status to prasugrel, their investigational anti-clotting treatment. The drug proved more effective in preventing heart attacks and strokes than Plavix, by Bristol-Myers Squibb and Co. and Sanofi-Aventis SA, although it raised bleeding risk, according to a patient study.

View Full Article in:

Bloomberg11

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Vice-President of Technology and Regulatory Affairs
AdvaMed
Washington DC, DC
Sr Product Manager Global Marketing (US/DA/00/0085/SL) - 14000009V3
Abbott
Chicago, IL
Director of Medicare Products
Bluegrass Family Health
Lexington, KY
Director of Medicare Products
Bluegrass Family Health
Lexington, KY
Vice President, Information Technology
HealthPartners
MN